Shots:

• The P-IIa trial evaluates the safety, efficacy & tolerability of SLS009 + aza/ven in r/r AML patients (n=10 & 11) at 45 & 60 mg (QW) or 30mg (BIW). Targets include response rate (RR), median survival & identifying biomarkers 
• As of Mar 15, 2024, the study depicted a 10% & 20% RR with 45 & 60mg & a 50% RR with 30mg (BIW). The study also showed ≥50% bone marrow blast reduction in 67% of patients across all dose levels whereas the median survival rate was not reached & the 1st patient achieving CR remained leukemia-free 9mos. post-enrollment
• Patients with identified biomarkers depicted a 100% RR at 30mg (BIW) & 57% across all dose levels. The company also reported the completion of patient enrollment in the P-III (REGAL) trial of GPS in AML

Ref: Sellas | Image: Sellas

Related News:- SELLAS Reports Updated Results from its P-IIa Study of SLS009 (formerly GFH009) for R/R Acute Myeloid Leukemia (AML)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com